Lapides Asset Management LLC lifted its holdings in Trinity Biotech (NASDAQ:TRIB) by 3.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,211,900 shares of the company’s stock after acquiring an additional 38,500 shares during the quarter. Trinity Biotech accounts for 1.4% of Lapides Asset Management LLC’s holdings, making the stock its 29th biggest position. Lapides Asset Management LLC owned approximately 5.04% of Trinity Biotech worth $6,241,000 as of its most recent SEC filing.
Other hedge funds have also recently added to or reduced their stakes in the company. Deutsche Bank AG lifted its stake in shares of Trinity Biotech by 3,969,200.0% in the fourth quarter. Deutsche Bank AG now owns 39,693 shares of the company’s stock worth $202,000 after buying an additional 39,692 shares in the last quarter. Millennium Management LLC raised its stake in Trinity Biotech by 20.8% during the fourth quarter. Millennium Management LLC now owns 403,587 shares of the company’s stock worth $2,058,000 after purchasing an additional 69,469 shares during the period. Hunter Associates Investment Management LLC raised its stake in Trinity Biotech by 10.9% during the fourth quarter. Hunter Associates Investment Management LLC now owns 711,185 shares of the company’s stock worth $3,627,000 after purchasing an additional 70,174 shares during the period. Adirondack Research & Management Inc. raised its stake in Trinity Biotech by 22.2% during the fourth quarter. Adirondack Research & Management Inc. now owns 408,337 shares of the company’s stock worth $2,083,000 after purchasing an additional 74,162 shares during the period. Finally, Fondren Management LP purchased a new position in Trinity Biotech during the fourth quarter worth about $510,000. Institutional investors own 70.35% of the company’s stock.
Shares of Trinity Biotech stock opened at $4.48 on Friday. The company has a market capitalization of $95.23 million, a P/E ratio of 17.23 and a beta of 1.34. The company has a quick ratio of 3.49, a current ratio of 5.03 and a debt-to-equity ratio of 1.45. Trinity Biotech has a 52-week low of $4.46 and a 52-week high of $4.46.
Trinity Biotech (NASDAQ:TRIB) last issued its quarterly earnings data on Tuesday, May 1st. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.03). Trinity Biotech had a positive return on equity of 3.26% and a negative net margin of 41.38%. The company had revenue of $23.80 million for the quarter.
A number of equities research analysts have weighed in on TRIB shares. Zacks Investment Research cut shares of Trinity Biotech from a “hold” rating to a “sell” rating in a research report on Thursday, January 25th. ValuEngine cut shares of Trinity Biotech from a “hold” rating to a “sell” rating in a report on Friday, February 2nd.
Trinity Biotech Company Profile
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease, sexually transmitted diseases, respiratory infections, epstein barr virus, and other viral pathogens; and products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a high risk of developing diabetes.
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.